FDG positron emission tomography (PET) imaging in gynaecological cancers;La TEP au [18F]-fluoro-2-désoxyglucose dans l'imagerie des cancers gynécologiques

Gynecologie Obstetrique et Fertilite

Volumn 29, Issue 11, 2001, Pages 775-798

  Talbot, J N ^a   Grahek, D ^a   Kerrou, K ^a   Younsi, N ^a   De Beco, V ^a   Colombet Lamau, C ^a   Petegnief, Y ^a   Cailleux, N ^a   Montravers, F ^a  

^a HÔPITAL TENON   (France)

Author keywords

Breast cancer; Cancer of uterus cervix; CDET; Ovarian cancer; PET; 18F FDG

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DEOXYGLUCOSE; DIAGNOSTIC AGENT; FLUORINE;

BREAST CANCER; CANCER INVASION; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; FRANCE; GYNECOLOGIC CANCER; HUMAN; IMAGE ANALYSIS; LYMPH NODE METASTASIS; OVARY CANCER; REVIEW; SCINTILLATION CAMERA; TREATMENT INDICATION; UTERINE CERVIX CANCER; BREAST TUMOR; FEMALE GENITAL TRACT TUMOR; OVARY TUMOR; SCINTISCANNING; TUMOR RECURRENCE; UTERINE CERVIX TUMOR;

BREAST NEOPLASMS; CERVIX NEOPLASMS; DEOXYGLUCOSE; ENGLISH ABSTRACT; FEMALE; FLUORINE RADIOISOTOPES; GENITAL NEOPLASMS, FEMALE; HUMAN; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034747412     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/S1297-9589(01)00197-7     Document Type: Short Survey

References (88)

1. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study
2. Tomographie par émission de positons (TEP) et [F-18]-fluorodésoxyglucose (FDG) en cancérologie
3. La gamma-caméra à détection de coïncidence: I principe, compromis, utilisation pour la scintigraphie conventionnelle
4. Preliminary results for positron emission mammography: Real-time functional breast imaging in a conventional mammography gantry
5. Technique to obtain positron emission mammography images in registration with x-ray mammograms
6. CT and 18F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers
7. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: Preliminary experience
8. Prevalence of adverse reaction to positron emitting radiopharmaceuticals in nuclear medicine
9. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer
10. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer
11. Excess muscle FDG uptake in an euglycaemic patient that is corrected by fasting
12. La tomographie par émission de positons au [18F]-fluoro-2-désoxyglucose: Revue de la littérature et de nos résultats dans les cancers extrapulmonaires
13. Use of a coincidence gamma camera to detect primary tumour with 18 fluoro-2-deoxy-glucose in cervical lymph node metastases from an unknown origin
14. Lesions of 4 mm and 5 mm detected with 18F-FDG using a dual head coincidence camera
15. F-18 FDG uptake in breast infection and inflammation
16. Clinical findings from normal screening by positron emission tomography at Himedic in Japan since october 1994
17. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease
18. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET
19. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
20. Positron tomographic assessment of estrogen receptors with breast cancer: Comparison with FDG-PET and in vitro receptor assays
21. Qualitative [18F] FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability
22. The potential of F-18-PET for the management of patients with breast cancer
23. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L [1-11C] tyrosine PET
24. Comparison of fluorine-18-fluorodeoxyglucose positron emission tomography and technetium-99m metoxyisobutylisonitrile scintimammography in the detection of breast tumours
25. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer
26. Diagnostic value of positron emission tomography for detecting breast cancer
27. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations
28. Positron emission tomography in breast cancer: A clinicopathological correlation of results
29. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures
30. 18-FDG imaging in breast cancer
31. Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET
32. Detection of cancer in augmented breasts by positron emission tomography
33. Incidental second primary in the breast detected by F-18 FDG positron emission tomography scan
34. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro [F-18]-D-glucose
35. Imaging primary tumors and axillary metastases with a dedicated breast PET camera
36. Comparison of dual-head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node metastasis
37. Diagnostic efficacy of gamma-camera coincidence PET in breast cancer
38. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer
39. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation
40. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis
41. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2 [fluorine-18]-fluoro-2-deoxy-D-glucose
42. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer
43. Prospective evaluation of fluorine 18-fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunochemistry
44. Axiltary lymph node metastases: Screening with [F-18] 2-deoxy-2-fluoro-D-glucose (FDG) PET
45. Staging of the axilla in breast cancer: Accurate m vivo assessment usmg positron emission tomography with 2 (fluorine-18) -fluoro-2-deoxy-D-glucose
46. Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer
47. Nuclear medicine approaches for detection of axillary lymph node metastases
48. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent and metastatic breast carcinoma
49. Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions
50. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases
51. Skeletal metastases from breast cancer: Uptake of 18F-fluoride measured with positron emission tomography in correlation with CT
52. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography
53. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy
54. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
55. Positron emission tomography using [18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
56. Positron emission tomography using [18F] -fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy
57. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy
58. Positron emission tomography with fluorine-18 fluorodeoxyglucose to evaluate response of early breast carcinoma treated with stereotaxic interstitital laser therapy
59. Value of 18F-fluorodeoxyglucose positron tomography in staging of recurrence breast carcinoma
60. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients
61. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer
62. 18F] FDG)
63. Metabolic characterization of ovarian tumors with positron-emission tomography and F-18fluorodeoxyglucose
64. 18F-fluorodeoxyglucose PET in ovarian carcinoma: Methodology and preliminary results
65. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography
66. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma
67. Recurrent ovarian carcinoma: Is there a place for surgery?
68. Experience with positron emission tomography (PET) scans in patients with ovarian cancer
69. Whole-body positron emission tomography with 2 [18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma
70. A prospective evaluation of whole body FDG-PET, CT scan and immunoscintigraphy in the detection of ovarian carcinoma recurrences
71. The clinical role of FDG PET in the management of residual and/or recurrent ovarian carcinoma
72. Potential cut savings by F-18-FDG PET as an alternative to second look laparotomy in ovarian cancer
73. Impact of whole body PET FDG in the early detection or recurrent ovarian cancer
74. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report
75. Role of whole body FDG-PET in management of patients with recurrent ovarian cancers
76. Initial findings of a hybrid positron emission tomography camera system for the identification and monitoring of ovarian cancer
77. Detection of recurrence of ovarian cancer using [F18] -FDG scan performed on a dual-head coincidence gamma-camera (CDET)
78. Peritoneal carcinosis, the role of FDG-PET
79. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations
80. Imaging of uterine carcinoma by carbon-11-methionine and PET
81. FDG-PET evaluation of carcinoma of the cervix
82. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: A surgicopathologic study
83. Evaluation of FDG PET in patients with cervical cancer
84. 18F FDG PET in clinical assessment of primary uterine cervical carcinoma/detection and correlation with tumor oxygen partial pressure
85. Metastatic lymph nodes in patients with cervical cancer: Detection with MR imaging and FDG PET
86. Early diagnosis and evaluation of therapy in postoperative recurrent cervical cancers by positron emission tomography
87. FDG PET in patients with cervical cancer of uterus: Experience in patients with clinically no evidence of disease
88. La scintigraphie au FDG réalisée à l'aide d'une caméra "hybride" TEDC, un outil diagnostique performant pour la détection des récidives du cancer du sein